The FDA has approved the first mRNA-based seasonal flu vaccine, mFLUSIVA, specifically for adults aged 50 and older to improve protection during flu season.
This milestone marks a significant advancement in vaccine technology, potentially paving the way for more effective and rapidly adaptable drugs in the future.
Health experts are optimistic that this new approach will enhance public health outcomes, with distribution expected to begin ahead of the upcoming winter.